Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 12/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2310619 | 0.84 | ALDH1A1 (0.37) | ALDH1A1MAPTSMN1; SMN2MCHR1POLB | |
| SCHEMBL13987235 | 0.72 | MCHR1 (0.40) | MCHR1KDM4E | |
| SCHEMBL12387508 | 0.71 | MCHR1 (0.38) | MCHR1KCNH2HTR2C | |
| SCHEMBL9505596 | 0.70 | CA1 (0.55) | ALDH1A1MAPTSMN1; SMN2MCHR1POLB | |
| Hydrochloric Acid SCHEMBL2309049 | 0.70 | MCHR1 (0.37) | MCHR1KCNH2HTR2C | |
| SCHEMBL13988036 | 0.68 | HSD17B3 (0.44) | MCHR1 | |
| SCHEMBL2315501 | 0.68 | MCHR1 (0.36) | MCHR1KCNH2HTR2C | |
| SCHEMBL5737230 | 0.68 | CA1 (0.42) | ALDH1A1MAPTSMN1; SMN2MCHR1KDM4E | |
| SCHEMBL14692395 | 0.67 | GSK3B (0.50) | ALDH1A1MAPTSMN1; SMN2POLBKDM4E | |
| SCHEMBL11679626 | 0.66 | MAPT (0.58) | ALDH1A1MAPTSMN1; SMN2KCNH2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989445-B2 | Thienopyrimidone compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-20100069362-A1 | Thienopyrimidone compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069362-A1 | Thienopyrimidone compound | MC1R, MC2R, MC5R | ALDH1A1 831/4885MAPT 4358/4885SMN1; SMN2 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.